Pardes Biosciences Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Pardes Biosciences's estimated annual revenue is currently $6.4M per year.(i)
  • Pardes Biosciences's estimated revenue per employee is $126,000

Employee Data

  • Pardes Biosciences has 51 Employees.(i)
  • Pardes Biosciences grew their employee count by 31% last year.

Pardes Biosciences's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chairman and CEOReveal Email/Phone
3
VP, FinanceReveal Email/Phone
4
General Counsel and Corporate SecretaryReveal Email/Phone
5
Accounts Payable ManagerReveal Email/Phone
6
Senior QA ConsultantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$212.8M10635%$65MN/A
#2
$35.6M24718%N/AN/A
#3
$45M299-4%$102.6MN/A
#4
$3.2M30-25%$21.3MN/A
#5
$34M2260%$42.9MN/A
#6
$3.6M34-28%$35MN/A
#7
$0.8M10N/AN/AN/A
#8
$12.6M90-9%N/AN/A
#9
$17.4M1240%$96.4MN/A
#10
$5.2M49-25%$75.6MN/A
Add Company

What Is Pardes Biosciences?

Better chemistry committed to the world's biggest problems

keywords:N/A

N/A

Total Funding

51

Number of Employees

$6.4M

Revenue (est)

31%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pardes Biosciences News

2022-04-17 - Loss-Making Pardes Biosciences, Inc. (NASDAQ:PRDS) Expected To Breakeven In The Medium-Term

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics...

2022-04-06 - Pardes Biosciences Inc.

Pardes Biosciences Inc is a clinical-stage biopharmaceutical company created for solving pandemic-sized problems, starting with COVID-19.

2022-03-22 - Pardes Biosciences Reports Full Year 2021 Financial Results ...

About Pardes Biosciences, Inc. Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.2M510%N/A
#2
$12.6M5131%N/A
#3
$3.5M51-7%N/A
#4
$9.1M5121%N/A
#5
$3.5M5224%N/A